A Prospective Multicenter Observational Study of Venous Thromboembolism after Gastric Cancer Surgery (SHISA-1601). by KAIDA Sachiko et al.
A Prospective Multicenter Observational Study
of Venous Thromboembolism after Gastric Cancer
Surgery (SHISA-1601).
著者 KAIDA Sachiko, MIYAKE Toru, MURATA Satoshi,
YAMAGUCHI Tsuyoshi, TATSUTA Takeshi, MURAKAMI
Koichiro, OKAUCHI Hiroshi, NISHIMURA Shoichi,
OHTA Hiroyuki, TSUCHIHASHI Hiroshi, KAWASAKI











This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial-4.0
International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the
online version of the article only. Usage and distribution for commercial purposes requires written
permission.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Research Article
Eur Surg Res
A Prospective Multicenter Observational 
Study of Venous Thromboembolism after 
Gastric Cancer Surgery (SHISA-1601)
Sachiko Kaida a    Toru Miyake a    Satoshi Murata a, b    Tsuyoshi Yamaguchi a    
Takeshi Tatsuta c    Koichiro Murakami c    Hiroshi Okauchi d    
Shoichi Nishimura d    Hiroyuki Ohta e    Hiroshi Tsuchihashi f    
Masayasu Kawasaki f    Katsushi Takebayashi a    Tomoharu Shimizu g    
Masaji Tani a    
a
 Department of Surgery, Shiga University of Medical Science, Otsu, Japan; b Cancer Center, 
Shiga University of Medical Science Hospital, Otsu, Japan; c Department of Surgery, 
Tesseikai Neurosurgical Hospital, Osaka, Japan; d Department of Surgery, Yasu Hospital, 
Yasu, Japan; e Department of Surgery, Higashi Oumi General Medical Center, Higashi-Oumi, 
Japan; f Department of Surgery, Bell Land General Hospital, Osaka, Japan; g Department of 
Medical Safety, Shiga University of Medical Science Hospital, Otsu, Japan
Keywords
Gastric cancer · Gastrectomy · Venous thromboembolism (VTE) · D-dimer · Soluble fibrin
Abstract
Introduction: This study aimed to clarify the frequency and risk factors of intercurrent venous 
thromboembolism (VTE) in patients undergoing major curative gastric cancer surgery. Meth-
ods: This prospective, multicenter, observational study included patients with gastric cancer 
who underwent radical gastrectomy at 5 hospitals between June 2016 and May 2018. Patients 
who were preoperatively administered anticoagulants were excluded. Results: A total of 126 
patients were eligible to participate. VTE occurred within 9 days postoperatively in 5 cases 
(4.0%; 2 symptomatic and 3 asymptomatic). Postoperative day (POD) 1 plasma D-dimer and 
soluble fibrin (SF) levels were significantly higher in the VTE group than in the non-VTE group. 
Receiver-operating characteristic curve (ROC) analysis indicated a statistically significant abil-
ity of POD 1 D-dimer and SF levels to predict postoperative VTE development after gastrec-
tomy; this finding was reflected by an area under the curve (AUC) of 0.97 (95% CI 0.92–1.0) 
and 0.87 (95% CI 0.74–1.0), respectively. Cutoff values of D-dimer (24.6 µg/mL) and SF (64.1 
µg/mL) were determined. Intraoperative blood transfusion (odds ratio [OR] 7.86), POD 1 D-
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dimer ≥24.6 µg/mL (OR 17.35), and POD 1 SF ≥64.1 µg/mL (OR 19.5) were independent pre-
dictive factors for postoperative VTE (p < 0.05). Conclusion: VTE occurred in 4.0% patients 
(1.6% symptomatic and 2.4% asymptomatic) after gastric cancer surgery; however, with an 
early diagnosis and anticoagulant therapy, no patients experienced progression. Careful ob-
servation of patients with a high risk for VTE, including intraoperative blood transfusion and 
high POD 1 D-dimer or SF levels, would contribute to the early detection of VTE.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Venous thromboembolism (VTE) includes both pulmonary thromboembolism (PE) and 
deep vein thrombosis (DVT). A cancer-bearing condition is an independent risk factor for VTE 
[1–3]. In fact, cancer patients reportedly have a 4- to 7-times higher risk of experiencing VTE 
than healthy people [4, 5]. Moreover, surgery is also a major risk factor for VTE, a life-threating 
postoperative complication [6]. In previous reports, 24.7% of patients who underwent lapa-
rotomy due to malignant abdominal tumors developed VTE [7]. In the absence of an effective 
VTE prophylaxis, the rate of asymptomatic DVT is reportedly 15–40% in patients who undergo 
major abdominal or pelvic surgery, resulting in a 0.2–0.9% rate of fatal PE events [4, 8, 9].
Thus, VTE is well known worldwide as a postoperative complication to avoid, for which 
several prevention guidelines have been proposed. The American Society of Clinical Oncology 
(ASCO) has issued guidelines for preventing VTE in cancer patients [10]. The VTE prevention 
guidelines issued by the American College of Chest Physicians (ACCP) in 2012 also advocated 
a VTE prevention method based on a risk score [11]. However, surgery in the abdominal 
region is widely defined as “a major surgery for cancer over 40 years of age,” and there are 
few reports on the risks, due to differences among races and organs. 
Gastric cancer remains the leading cause of cancer-related death worldwide, and radical 
resection is the most promising treatment to ensure long-term survival [12, 13]. Many retro-
spective studies have examined VTE after gastrectomy. Tanizawa et al. [14] reported a 7.5% 
incidence of preoperative VTE with gastric cancer in Japan. Within 2 years after surgery for 
gastric cancer, 2.5–7% of patients with VTE had symptoms, or the condition was incidentally 
identified when imaging studies were performed to evaluate a tumor or other disease status 
[15]. However, the incidence of VTE after gastric cancer surgery including asymptomatic VTE 
remains unknown.
This multicenter study aimed to prospectively examine the precise incidence of symp-
tomatic and asymptomatic VTE in patients undergoing radical gastric cancer surgery and 
then evaluate the risk factors for VTE.
Materials and Methods
Study Design
The Shiga Surgical Association-1601 study was a multicenter prospective observational study of post-
operative VTE in patients who underwent gastrectomy for gastric cancer at 5 hospitals in Japan. Between 
June 2016 and May 2018, consecutive gastric cancer patients scheduled for radical surgery were enrolled. 
The inclusion criteria were as follows: (1) diagnosis of histopathologically confirmed gastric cancer, 
(2) scheduled for curative gastrectomy and lymph node dissection, (3) an age ≥20 years at the time of 
consent, and (4) a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale. 
Those with a history of thromboembolic disease before surgery or severe renal insufficiency (creatinine 
clearance ≤30 mL/min), who were using any anticoagulant therapy before surgery, experienced severe 
complications, had a PS of ≥3 on the ECOG scale, or were pregnant were excluded. VTE prophylaxis after 
gastrectomy was chosen at the discretion of each facility.
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Data Collection and Variables
Patient characteristics (age, sex, body mass index [BMI], ECOG PS, and disease progression), preoper-
ative blood tests (hemoglobin, white blood cell [WBC] count, lymphocyte ratio, neutrophil ratio, platelet 
count, serum albumin, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creat-
inine, C-reactive protein [CRP], prothrombin time, activated partial thromboplastin time [APTT], and 
D-dimer), intraoperative outcomes (procedure, operation time, blood loss, and blood transfusions) and post-
operative outcomes (complications including VTE; POD 1 blood tests: WBC, platelet count, hemoglobin, 
D-dimer, and soluble fibrin [SF]; POD 7 blood tests: WBC, platelet count, hemoglobin, CRP, and D-dimer) were 
recorded on standardized forms. The patients were enrolled on the day of surgery. Registration was 
completed when the patient characteristics were entered on the registration form specified in the research 
registration address. After registering, the patient was assigned a registration number. 
Operative Technique
The standard procedure at our institutions was a distal, proximal, or total gastrectomy, with regional 
dissection of the lymph nodes according to the 15th edition of the Japanese Gastric Cancer Classification of 
Gastric Carcinoma [2]. In cases of clinical stage I tumors, laparoscopic gastrectomy with D1+ lymph node 
dissection was performed.
Outcome Measures
The primary end point of this study was to clarify the incidence of symptomatic and asymptomatic VTE 
during the observation period (30 days) after radical gastric cancer surgery. The secondary end point was to 
analyze the risk factors for VTE after gastric cancer surgery.
Surgical complications were classified according to the Clavien-Dindo (C-D) classification system [16]. 
Enhanced computed tomography (CT) or ultrasonography of the lower limb was performed to diagnose VTE 
postoperatively when symptoms of VTE such as respiratory distress, extremity edema, or leg pain were 
observed, or the postoperative blood test showed levels of SF ≥7.6 µg/mL or D-dimer ≥9.8 µg/mL on day 1 
despite no symptoms of VTE based on past reports [17].
Since this was an exploratory study, we set the target number of cases based on feasibility, i.e., 80 patients 
per year were undergoing gastric cancer surgery at the participating facilities; taking into consideration the 
nonqualifying cases, the enrollment of 120 cases was estimated over a 2-year case accumulation period.
Statistical Analysis
STATISTICAL analyses were performed with the Fisher exact test or Mann-Whitney U test as appro-
priate. Statistical calculations were performed using the Statistical Package for the Social Sciences v22.0 (IBM 
Institute, Armonk, NY, USA) and GraphPad Prism v8.0 (GraphPad Software, San Diego, CA, USA). For all 
analyses, differences were considered statistically significant at p < 0.05. Using these parameters, receiver-
operating characteristic (ROC) curves for D-dimer were constructed and quantified via area under the curve 
(AUC) analysis as well as the standard error of the mean and the corresponding 95% CI. The Youden Index 
was calculated as sensitivity + specificity – 1. Logistic regression models were used for the multivariate 
analyses to identify risk factors associated with the development of postoperative VTE. Two-sided p values 
< 0.05 were considered statistically significant.
Results
Patients’ Characteristics
A total of 136 patients were enrolled; 10 who were prospectively administered antico-
agulants were excluded. Finally, 126 patients were enrolled in the study and followed up for 
30 days postoperatively. Five patients developed VTE postoperatively; of these, 2 had symp-
tomatic thrombosis. One patient had underlying hepatitis B and liver cirrhosis and showed 
no symptoms of VTE; however, the POD 1 D-dimer and SF levels were high, and enhanced CT 
revealed portal vein thrombosis on POD 1. In the other patient, who had a central venous port 
before surgery, POD 9 D-dimer and SF levels were increased, and enhanced CT revealed a 
small thrombus adhering to the catheter tip. Among the VTE cases, 4 patients were adminis-
tered unfractionated heparin (UFH) for at least 1 week, so that the APTT was 1.5–2.5 times 
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the facility’s upper limit. Another patient with DVT of the leg was followed up but did not 
require any additional treatments since the symptoms resolved. No cases of VTE progression 
were observed during follow-up. 
Table 1 shows the characteristics of the VTE and non-VTE cases. There were no signif-
icant intergroup differences in patient background factors including age, sex, BMI, ECOG PS, 
histological type, clinical T classification, clinical N classification, or clinical stage according 
to the 15th Japanese Classification of Gastric Carcinoma. Table 2 compares the intraoperative 
outcomes and surgical procedures of the 2 groups. There were no significant intergroup 
differences in operative procedure, reconstruction method, percentage of open versus lapa-
roscopic procedures, lymph node dissection, operation time, or blood loss. However, signifi-
cantly more patients with VTE required intraoperative blood transfusions (7 cases [5.3%] vs. 
3 cases [60%], p = 0.0034).
Pre- versus Postoperative Blood Test Results
Comparison of the blood test results revealed no significant intergroup difference in 
preoperative values. However, significant intergroup differences were observed in the POD 
1 and POD 7 D-dimer and SF levels (Table 3).
VTE Prophylaxis and Postoperative Complications
VTE prophylaxis was performed by intermittent pneumatic compression (IPC) 126/126 
[100%]), wearing elastic stockings (125/126 [99%]), or anticoagulant drugs (85/126 
Table 1. Patients’ characteristics
Non VTE 
group (n = 121)
VTE 
group (n = 5)
p value
Age, years 69 (24–91) 72 (66–77) 0.39
Sex 0.59
Male 92 (76) 3 (60)
Body mass index 22.6 (16.2–32.2) 23.1 (19.0–24.7) 0.77
ECOG PS 0/1/2 101/14/6 3/1/1 0.28
Histological type 0.14
Differentiated 73 (60.3) 1 (20)
Undifferentiated 44 (36.4) 4 (80)
Other 4 (3.3) 0 (0)
pT classification1 0.27
T1a/T1b 60 (49.6) 2 (40)
T2 25 (20.7) 1 (20)
T3 17 (14.0) 1 (20)
T4 19 (15.7) 1 (20)
pN classification1 0.86
N0 84 (69.4) 3 (60)
N1 20 (16.5) 1 (20)
N2 12 (9.9) 1 (20)
N3 5 (4.1) 0 (0)
pStaging1 0.085
I 78 (64.5) 1 (20)
II 19 (15.7) 2 (40)
III 20 (16.5) 1 (20)
IV 4 (3.3) 1 (20)
Values are expressed as n (%) or median (range). 1 According to the 15th Japanese Classification of Gastric 
Carcinoma.
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[67.4%]). Enoxaparin sodium was most frequently used as a prophylaxis anticoagulant, but 
there was no significant intergroup difference. There was no difference between institutions 
in postoperative antithrombotic therapy, and IPC was used in 100% of cases during surgery 
and 82.5% of cases after surgery. Regarding postoperative outcomes, patients without VTE 
had a significantly higher occurrence of postoperative non-VTE complications than patients 
with VTE (C-D classification, p = 0.0093).
Patients with Positive D-Dimer and SF Test Results
D-dimer and SF data sets were obtained for 81 patients (64.3%). The mean POD 1 plasma 
D-dimer level of the VTE group was significantly higher than that of the non-VTE group 
(Fig. 1a). POD 1 plasma SF levels in the VTE group were also significantly higher than those 
in the non-VTE group (Fig. 1b). The ROC curve analysis indicated a statistically significant 
ability of POD 1 D-dimer and SF levels to predict postoperative VTE development after 
gastrectomy; these findings were reflected by an AUC value of 0.97 (95% CI 0.92–1.0) (Fig. 1c) 
and 0.87 (95% CI 0.74–1.0; Fig. 1d), respectively. The cutoff values of D-dimer (24.6 µg/mL) 
and SF (64.1 µg/mL) were determined. 
Uni- and Multivariate Analyses of VTE Predictive Factors
Results from the univariate analysis of the risk factors associated with the postoperative 
development of VTE are shown in Table 4. Age ≥70 years (p = 0.0425), intraoperative blood 
transfusion (p < 0.0001), POD 1 D-dimer level ≥24.6 µg/mL (p < 0.0001), and POD 1 SF ≥64.1 
µg/mL (p < 0.0001) were predictive of an increased risk of VTE development. However, no 
other clinical parameters were predictive of postoperative VTE development.
The multivariate analysis included only the 4 variables that showed statistical signif-
icance in the univariate analyses: age ≥70 years, intraoperative blood transfusion, and 
POD 1 D-dimer and SF levels. Among them, intraoperative blood transfusion (odds ratio 
[OR] 7.86; 95% CI 1.09–56.59; p = 0.0405), POD 1 D-dimer level ≥24.6 µg/mL (OR 17.35; 
Table 2. Intraoperative outcomes and surgical procedures
Non VTE 
group (n = 121)
VTE 
group (n = 5)
p value
Operative procedure 0.07
Distal gastrectomy 81 (66.9) 2 (40)
Total gastrectomy 37 (30.6) 2 (40)
Proximal gastrectomy 3 (2.5) 1 (20)
Reconstruction method 0.08
Billroth I 41 (33.9) 2 (40)
Roux-en-Y 77 (63.6) 2 (40)
Esophagogastrostomy 3 (2.5) 1 (20)
Approach >0.99
Open 63 (52.1) 3 (60)
Laparoscopic 58 (47.9) 2 (40)
Lymph node dissection >0.99
D1/D1+ 61 (50.4) 3 (60)
D2 60 (49.6) 2 (40)
Operation time, min 339 (165–652) 476 (252–602) 0.15
Bleeding, mL 200 (0–3695) 813 (18–2463) 0.18
Intraoperative blood transfusion 7 (5.8) 3 (60) 0.0034
Values are expressed as n (%) or median (range).
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95% CI 2.49–120.8, p = 0.00395), and POD 1 SF level ≥64.1 µg/mL (OR 19.5; 95% CI 
1.81–209.6, p = 0.0142) were independent predictive factors for postoperative VTE 
development.
Discussion
The frequency of VTE after gastric cancer surgery has been reported in a randomized controlled 
trial in Korea [18]. The overall VTE frequency was 2.1%. All patients underwent duplex ultraso-
nography (DUS) routinely on postoperative day 4, after which they were followed up for clinical 
symptoms to identify VTE. In Japan, it has been reported that 7.2% of DVT was found by lower limb 
echo on 7 days after surgery for gastric cancer in a single-center study [19]. However, the incidence 
of VTE after gastric cancer surgery, including asymptomatic VTE diagnosed by more objective and 
sensitive images of CT scans, remains unknown. Therefore, it is worthwhile to report the frequency 
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Table 4. Univariate and multivariate analysis for VTE risk factors
Univariate analysis Multivariate analysis
odds ratio 95% CI p value odds ratio 95% CI p value
Age ≥70 years 1.21 0.20–7.11 0.0425 1.31 0.13–13.65 0.8212
Male sex 2.1 0.27–16.17 0.4061
ECOG PS ≥2 4.17 0.09–185.5 0.1622
BMI ≥22 1.17 0.20–6.829 0.8615
Intraoperative blood transfusion + 18.01 0.67–483.5 <0.0001 7.86 1.09–56.59 0.0405
Operation time ≥300 min 2.1 0.33–13.3 0.485
Bleeding ≥300 mL 2.6 0.642–16.1 0.2808
Open surgery 1.35 0.23–7.83 0.7506
Pathological stage ≥III 0.21 0.03–1.62 0.0575
D-dimer ≥24.6 μg/mL on POD1 34.85 0.06–22232 <0.0001 17.35 2.49–120.8 0.004
Soluble fibrin ≥64.1 μg/mL on POD1 38.45 0.38–3868 <0.0001 19.5 1.81–209.6 0.0142
Fig. 1. Comparison of D-dimer (a) and SF (b) values on the first day after surgery. The ROC curve for the rec-
ognition of D-dimer (c) and SF (d). AUC, area under the curve; CI, confidence interval; POD, postoperative 
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by a contrast CT scan taken based on elevated of D-dimer and/or SF levels after gastric cancer 
surgery in a multicenter prospective study. In this study, we found VTE in 4.0% patients (1.6% 
symptomatic and 2.4% asymptomatic) after gastric cancer surgery. 
There are many research reports on perioperative VTE prophylaxis in gastrointestinal 
surgery, and the ASCO guidelines suggest that VTE prophylaxis be administered at least 7–10 
days after cancer surgery [10]. Especially in patients with a high risk of VTE, a maximum of 4 
weeks of continuous VTE prophylaxis should be considered. The ACCP guidelines for the 
prevention of VTE recommend low-molecular-weight heparin (LMWH) for patients under-
going abdominal surgery for cancer [20]. Widely used LMWH is characterized as having a high 
anti-Xa/thrombin activity ratio compared to UFH and relatively less able to inhibit thrombin; 
it therefore has less influence on platelets and fewer hemorrhage-related side effects [21–23]. 
In a large randomized controlled trial in South Korea, postoperative VTE occurred significantly 
higher frequently in the IPC-only group compared to the IPC + LMWH group (3.6 vs. 0.6%; p = 
0.008), and the incidence of postoperative bleeding complications was significantly higher in 
the IPC + LMWH group than in the IPC-only group (9.1 vs. 1.2%; p < 0.001) after gastric cancer 
surgery [18]. From Japan, Osaki et al. [19] performed lower limb echo before and 7 days after 
surgery for gastric cancer, and reported a DVT of 4.4 and 7.2%, respectively.
We conducted this study to determine the incidence of patients who develop VTE after 
radical surgery for gastric cancer through a multicenter study in Japan. In this study, all 
surgeons at the 5 institutes used enoxaparin sodium postoperatively and no adverse bleeding 
events occurred. This study clarified that the incidence of VTE after radical gastric cancer 
surgery was 4.0%. Of the 5 VTE cases (4.0%), 3 (60%) were identified within 2 days after 
surgery; in all 3, enoxaparin sodium was used only once. This study found that LMWH admin-
istered from POD 2 could not completely prevent postoperative VTE.
Li et al. [24] reviewed 8,611 reports and identified the positive risk factors for VTE of age, 
radiation, need for blood transfusion, and operative time. Nielsen et al. [25] also reported that blood 
transfusion was a major risk factor for VTE in bariatric surgery. These reports demonstrated the 
need to monitor thrombosis markers and patient symptoms in cases in which blood transfusion 
was performed during surgery, and to evaluate imaging studies immediately to diagnose VTE and 
start treatment. Our study also showed that in elderly patients (≥70 years old), intraoperative 
blood transfusion could be a risk factor for VTE development after gastrectomy.
D-dimer is generally thought to increase in patients who are old, have a history of cancer, 
and undergo surgery [5]. In this study, D-dimer on days 1 and 7 after surgery for gastric cancer 
was also increased in patients who did not develop VTE, compared to preoperatively (Table 
3). However, patients with high D-dimer on the first day after surgery still had a significantly 
higher incidence of VTE. This is a new finding that goes beyond the conventional knowledge 
of high D-dimer level after cancer surgery. Together with the SF levels, high D-dimer levels on 
the first day after surgery could be used as a high predictor of VTE development after surgery. 
For predicting VTE, no previous reports suggested a detailed cutoff value for postoper-
ative VTE in gastric cancer patients. Kimura et al. [26] reported that after gastrointestinal 
cancer surgery, D-dimer on the 7th day after the operation was significantly higher than that 
on the 3rd day after the operation. However, there has been no report showing the cut-off 
value of D-dimer that predicts VTE on the first day after surgery. Therefore, we focused on 
the blood test results from POD 1 for early VTE detection. The POD 1 D-dimer and SF levels 
were significantly higher in the VTE group, and the cutoff values obtained by drawing the ROC 
curve were 24.6 µg/mL for D-dimer and 64.1 µg/mL for SF. Imaging tests based on the 
elevated POD 1 D-dimer and SF levels could enable the early detection of VTE, which may lead 
to early anticoagulant therapy. Even in this study, an abnormal POD 1 D-dimer or SF levels 
led to the early diagnosis of asymptomatic VTE; as a result, rapid anticoagulation treatment 
was provided, resulting in a good prognosis without VTE deterioration. 
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One of the limitations of this study was that prophylaxis anticoagulants to prevent post-
operative VTE were used only in 67.4% of patients. It is unclear whether the low incidence of 
VTE was related to postoperative prophylaxis anticoagulant use starting on POD 2. In addition, 
5 cases of VTE were insufficiently powered to analyze the risk factors for VTE. It is expected 
that cases will be further accumulated under the unified use of postoperative prophylaxis 
anticoagulants and that the risk factors for VTE development will be analyzed in detail.
Another limitation was that POD 1 and POD 7 D-dimer and SF levels were obtained in 
64.3% of cases. This was because the measurements could not be taken at some general 
hospitals due to medical insurance problems. However, our study findings suggest the signif-
icance of a high D-dimer or SF value in the early postoperative period and demonstrate the 
real incidence of VTE after radical gastric cancer surgery; therefore, we will be able to conduct 
this validation study to confirm the significance of early postoperative D-dimer and SF levels 
as risk factors for the development of postoperative DVT in gastric cancer surgery.
Conclusion
VTE occurred in 4.0% of patients (1.6% symptomatic and 2.4% asymptomatic) after 
gastric cancer surgery, without VTE deterioration due to the early diagnosis of VTE and early 
anticoagulant therapy. The careful observation of patients with high-risk factors and predictive 
factors for VTE, including intraoperative blood transfusion and high POD 1 D-dimer or SF 
level, would contribute to the early detection of VTE.
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